InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reaches Milestone in Human Clinical Study, Notes Growing Availability of DehydraTECH-Enabled Products
July 28, 2021

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reaches Milestone in Human Clinical Study, Notes Growing Availability of DehydraTECH-Enabled Products

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reached a significant point in its second human clinical study of 2021: HYPER-H21-2. The company announced that dosing has been completed in the study, which was comprised of 16 human volunteers who were pre- or mildly hypertensive; each participant received three separate doses of 150 mg each of DehydraTECH(TM) 2.0-enabled CBD versus a placebo. The study also included 24-hour continuous monitoring of blood pressure and heart rate, as well as evaluations of central arterial stiffness, physical activity and sleep quality. This key information will be assessed to evaluate the human response to DehydraTECH 2.0-enabled CBD. The company anticipates beginning a third human clinical study, HYPER-H21-3, following analysis of results from the first and second studies. In addition, Lexaria announced the expansion of its intellectual property portfolio with the allowance of its second patent in Japan. The patent is the 21st patent the company has been granted. Lexaria also noted that more than 7,000 stores across the country sell products that use its exclusive DehydraTECH technology. Some of those products include Cannadips, the original tobacco-free and nicotine-free CBD pouch; a growing number of New World CBD SKUs; and next-generation CHYLOSOMA(TM) formulations of CBD, CBG and CBN topical skin offerings. “Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients,” said Lexaria CEO Chris Bunka. “We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.”

To view the full press releases, visit https://ibn.fm/S0D9c and https://ibn.fm/98Kbp

About Lexaria Bioscience Corp.

Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit http://www.LexariaBioScience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).